Purpose: To image inflammation and monitor therapeutic response to anti-inflammatory intervention using 2-deoxy-2-[F]fluoro-D-glucose ([F]FDG) positron emission tomography (PET) in a preclinical model of acute lung injury (ALI).
Procedures: Mice were intratracheally administered lipopolysaccharide (LPS, 2.5 mg/kg) to induce ALI or phosphate-buffered saline as the vehicle control. A subset of mice in the ALI group received two intraperitoneal doses of dexamethasone 1 and 24 h after LPS. [F]FDG PET/CT was performed 2 days after the induction of ALI. [F]FDG uptake in the lungs was quantified by PET (%ID/mL and standardized uptake value (SUV)) and ex vivo γ-counting (%ID/g). The severity of lung inflammation was determined by quantifying the protein level of inflammatory cytokines/chemokines and the activity of neutrophil elastase and glycolytic enzymes. In separate groups of mice, flow cytometry was performed to estimate the contribution of individual immune cell types to the total pulmonary inflammatory cell burden under different treatment conditions.
Results: Lung uptake of [F]FDG was significantly increased during LPS-induced ALI, and a decreased [F]FDG uptake was observed following dexamethasone treatment to an intermediate level between that of LPS-treated and control mice. Protein expression of inflammatory biomarkers and the activity of neutrophil elastase and glycolytic enzymes were increased in the lungs of LPS-treated mice versus those of control mice, and correlated with [F]FDG uptake. Furthermore, dexamethasone-induced decreases in cytokine/chemokine protein levels and enzyme activities correlated with [F]FDG uptake. Neutrophils were the most abundant cells in LPS-induced ALI, and the pattern of total cell burden during ALI with or without dexamethasone therapy mirrored that of [F]FDG uptake.
Conclusions: [F]FDG PET noninvasively detects lung inflammation in ALI and its response to anti-inflammatory therapy in a preclinical model. However, high [F]FDG uptake by bone, brown fat, and myocardium remains a technical limitation for quantification of [F]FDG in the lungs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027262 | PMC |
| http://dx.doi.org/10.1007/s11307-023-01813-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.
Eur J Nucl Med Mol Imaging
December 2024
Department of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng Dist, Beijing, 100034, China.
Purpose: CD38 is a glycoprotein highly specific to multiple myeloma (MM). Therapeutics using antibodies targeting CD38 have shown promising efficacy. However, the efficient stratification of patients who may benefit from daratumumab (Dara) therapy and timely monitoring of therapeutic responses remain significant clinical challenges.
View Article and Find Full Text PDFFirst-generation high-affinity ST14 radiopharmaceutical: Design, synthesis, and preclinical PET imaging evaluation for pancreatic cancer detection.
Bioorg Chem
December 2024
Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 210000, China. Electronic address:
The non-specificity of F-FDG, coupled with high false-positive rates in pancreatitis, underscores an unmet clinical need for using specific positron emission tomography (PET) radiopharmaceuticals in noninvasive pancreatic cancer detection. ST14, a trypsin-like protease and a member of the type II transmembrane serine protease family, is overexpressed in various solid malignancies, including pancreatic cancer. This study aimed to develop a Ga-labeled PET radiopharmaceutical targeting ST14 for pancreatic cancer detection.
View Article and Find Full Text PDFPrognostic value of metabolic tumor volume on [F]FDG PET/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer.
Cancer Imaging
December 2024
Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC) Dresden, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstraße 74, Dresden, 01307, Germany.
Purpose: Staging of non-small cell lung cancer (NSCLC) is commonly based on [F]FDG PET/CT, in particular to exclude distant metastases and guide local therapy approaches like resection and radiotherapy. Although it is hoped that PET/CT will increase the value of primary staging compared to conventional imaging, it is generally limited to the characterization of TNM. The first aim of this study was to evaluate the PET parameter metabolic tumor volume (MTV) above liver background uptake as a prognostic marker in lung cancer.
View Article and Find Full Text PDFIs there a comparable Mp-MRI for incidental prostate uptake on 18 F-FDG PET/CT?
World J Surg Oncol
December 2024
Department of Urology, Başaksehir Çam and Sakura City Hospital, Istanbul, Turkey.
Purpose: Although 18 F-FDG-PET/CT is helpful in defining many types of cancer, localized prostate cancer should not be treated with this technique. This study describes the use of multi-parametric MRI (mpMRI) to characterize incidental 18 F-FDG uptake in the prostate.
Methods And Materials: While 18 F-FDG-PET/CT is useful for characterizing a variety of cancers, it is not advised for prostate cancer that is localized.
Clinico-pathological factors and [F]FDG PET/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma.
BMC Med Imaging
December 2024
Department of Nuclear Medicine, Hospital 108, Hanoi, Vietnam.
Objective: Identifying prognostic markers for clinical outcomes is crucial in selecting appropriate treatment options for patients with radioiodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC). The aim of this study was to investigate the prognostic value of clinico-pathological features and semiquantitative [F]FDG PET/CT metabolic parameters in predicting progression-free survival (PFS) in DTC patients with RAI-R.
Patients And Methods: This prospective cohort study included 110 consecutive RAI-R DTC patients who were referred for [F]FDG PET/CT imaging.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!